WELLESLEY, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate in the upcoming investor conferences detailed below.
TD Cowen 45th Annual Health Care Conference
Format: Formal presentation and one-on-one investor meetings
Date: March 4, 2025
Time: 9:50 a.m. ET
Webcast: Click here
Leerink’s Global Healthcare Conference 2025
Format: Fireside chat and one-on-one investor meetings
Date: March 10, 2025
Time: 10:00 a.m. ET
Webcast: Click here
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.
Investors
Chris Brinzey
ICR Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
339-970-2843
Media
Jon Yu
ICR Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
475-395-5375
| Last Trade: | US$3.01 |
| Daily Volume: | 0 |
August 12, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
